Krakow, Poland – September 9, 2020 – Ryvu Therapeutics (WSE:RVU), a clinical-stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology, announced today that the company will present at the upcoming H.C. Wainwright & Co. 22nd Annual Global Investment Conference, taking place September 14 – 16, 2020.
Krzysztof Brzózka, Chief Scientific Officer at Ryvu Therapeutics, is scheduled to present a corporate overview and research update on Wednesday, September 16, at 1:30 PM ET (19:30 CEST).
For registration and additional information about the conference, please visit: https://hcwevents.com/#toggle-id-4